Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
10/2000
10/24/2000US6136862 Intravenously administering an organic acid, ester, or salt thereof
10/24/2000US6136839 Using a sulfone or sulfoamide benzene compound
10/24/2000US6136825 Sulfonamide compounds having 5-HT receptor activity
10/24/2000US6136805 Quinoxaline dione derivatives, their production and their use in medicaments
10/24/2000US6136799 Cosolvent formulations
10/24/2000US6136787 Interleukin 1β protease and interleukin 1β protease inhibitors
10/24/2000US6136563 With defined substitutions for enhanced affinity for its receptor
10/24/2000US6136367 Composition and its use as a food supplement or for lowering lipids in serum
10/24/2000CA2221148C Muscle trophic factor
10/24/2000CA2137445C Naphtalene derivates, process for their preparation and pharmaceutical compositions containing them
10/19/2000WO2000061779A1 49 human secreted proteins
10/19/2000WO2000061774A2 Bone morphogenic proteins
10/19/2000WO2000061757A1 Tumor necrosis factor homologs and nucleic acids encoding the same
10/19/2000WO2000061628A1 49 human secreted proteins
10/19/2000WO2000061620A1 49 human secreted proteins
10/19/2000WO2000061619A1 Protein/polypeptide-k obtained from momordica charantia and a process for the extraction thereof
10/19/2000WO2000061587A1 Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines
10/19/2000WO2000061582A1 Substituted fused imidazole derivatives
10/19/2000WO2000061581A1 Amine derivatives
10/19/2000WO2000061576A1 Triarylimidazoles
10/19/2000WO2000061568A2 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof
10/19/2000WO2000061556A1 Nitrogen-containing heterocyclic compounds and benamide compounds and drugs containing the same
10/19/2000WO2000061551A2 Pyrimidine-2-one derivatives as integrin receptor ligands
10/19/2000WO2000061542A1 Caspase inhibitors and the use thereof
10/19/2000WO2000061539A1 3-bicycloaryl-2-aminomethyl bicycloalkanes as serotonine reuptake inhibitors
10/19/2000WO2000061189A2 Water-soluble compositions of bioactive lipophilic compounds
10/19/2000WO2000061180A2 Products and methods for treating ptp lar related diseases
10/19/2000WO2000061177A1 Composition based on oppositely-charged polypeptides
10/19/2000WO2000061140A1 Anticonvulsant derivatives useful in maintaining weight loss
10/19/2000WO2000061139A1 Anticonvulsant derivatives useful in reducing blood glucose levels
10/19/2000WO2000061138A1 Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
10/19/2000WO2000061137A1 Anticonvulsant derivatives useful in lowering lipids
10/19/2000WO2000061129A2 S-hydroxynefazodone
10/19/2000WO2000061112A2 Solubilized pharmaceutical composition for parenteral administration
10/19/2000WO2000060956A1 Hydrogel-forming system with hydrophobic and hydrophilic components
10/19/2000WO2000060953A2 Methods for stabilizing liquid nutritional products and products so stabilized
10/19/2000WO2000060950A1 Dietary supplement derived from fermented milks for the prevention of osteoporosis
10/19/2000WO2000060932A1 Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding 4e-bp1
10/19/2000WO2000041505A3 Anthranilic acid derivatives
10/19/2000WO2000035952A3 Compounds for control of eating, growth and body weight
10/19/2000WO2000034485A3 Beta-1,3-galactosyltransferase homologs
10/19/2000WO2000024437A3 Textured and porous silicone rubber
10/19/2000WO2000019883A9 Compositions and methods of disease diagnosis and therapy
10/19/2000WO2000012720A8 Elongase genes and uses thereof
10/19/2000DE19917505A1 Treating cytokine-mediated diseases, e.g. asthma, allergy, eczema, rheumatoid arthritis or transplant rejection, using new or known maduraphthalazine derivatives
10/19/2000DE19916837A1 New di- or tetrahydro-benzoazulene derivatives, are integrin inhibitors useful e.g. for treating thrombosis, coronary heart disease, arteriosclerosis, tumors, osteoporosis or rheumatoid arthritis
10/19/2000DE19915465A1 Verwendung eines Caspase-Inhibitors zur Proliferationshemmung von Zellen und Verwendung eines oder mehrerer Caspase-Inhibitors/en zur Behandlung von Erkrankungen beruhend auf Lymphozyten-Hyperproliferation oder zur Suppression einer Immunantwort durch Lymphozyten Using a Caspase inhibitor for the inhibition of proliferation of cells and using one or more caspase inhibitor / s for the treatment of diseases based on lymphocyte hyperproliferation or for suppression of an immune response by lymphocytes
10/19/2000CA2370767A1 49 human secreted proteins
10/19/2000CA2370523A1 49 human secreted proteins
10/19/2000CA2369971A1 Aryl or heteroaryl fused imidazole derivatives, their pharmaceutical compositions and agents, and uses thereof
10/19/2000CA2369908A1 Protein/polypeptide-k obtained from momordica charantia and a process for the extraction thereof
10/19/2000CA2369619A1 Caspase inhibitors and the use thereof
10/19/2000CA2369230A1 Anticonvulsant derivatives useful in maintaining weight loss
10/19/2000CA2369225A1 S-hydroxynefazodone
10/19/2000CA2369156A1 Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding 4e-bp1
10/19/2000CA2369103A1 Nitrogen-containing heterocyclic compounds and benamide compounds and drugs containing the same
10/19/2000CA2368840A1 3-bicycloaryl-2-aminomethyl bicycloalkanes as serotonine reuptake inhibitors
10/19/2000CA2368049A1 Integrin receptor ligands
10/19/2000CA2365945A1 Products and methods for treating ptp lar related diseases
10/19/2000CA2365918A1 49 human secreted proteins
10/19/2000CA2365917A1 Bone morphogenic proteins
10/19/2000CA2365913A1 Tumor necrosis factor receptor homologs and nucleic acids encoding the same
10/18/2000EP1044975A1 Stable crystalline salts of 5-methyltetrahydrofolic acid
10/18/2000EP1044970A1 Aminotriazole compounds, process for their preparation and pharmaceutical compositions containing them
10/18/2000EP1044215A1 Anti-inflammatory phenylalanine derivatives
10/18/2000EP1044189A1 Aryl fused azapolycyclic compounds
10/18/2000EP1044024A1 Use of pigmented retinal epithelial cells for creation of an immune privilege site
10/18/2000EP1044016A1 Stabilised insulin compositions
10/18/2000EP1044015A1 Formulations for amylin agonist peptides
10/18/2000EP1044009A2 Methods and compositions employing red rice fermentation products
10/18/2000EP1044007A1 The use of mannose for combating protein loss enteropathy
10/18/2000EP1043993A2 Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men and method to study the dyssynergia in male rodents
10/18/2000EP1043982A2 Lipase inhibiting polymers
10/18/2000EP1043981A2 Fat-binding polymers combined with lipase inhibitors
10/18/2000EP1043980A2 Method of reducing craving in mammals
10/18/2000EP0988274A4 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
10/18/2000CN1270585A Substituted 1,2,3,4-tetrahydronaphthalene derivatives
10/18/2000CN1270526A Metal compounds, mixed or sulphated as phosphate binders
10/18/2000CN1270516A Pharmaceutical preparation comprising colodronate as active ingredient and silicified microcrystalline cellulose as excipient
10/18/2000CN1270060A Enteric insulin capsule for treating diabetes
10/18/2000CN1270039A Chewing tablets of pilose antler, deerhorn and deer bone and preparing process thereof
10/18/2000CN1057466C Capsule for improving blood circulation and reducing fat
10/18/2000CN1057448C Method for prepn. of medicinal introducing bag for treating diabetes mellitus
10/18/2000CN1057442C Preparing method for composition pharmaceutique for parenteral injection
10/17/2000US6133458 Benzo[B]indeno[2, 1-D]thiophene compounds, intermediates, compositions, and methods
10/17/2000US6133454 Method for preparing a substituted perhydroisoindole
10/17/2000US6133311 Method for preventing or treating elevated blood lipid level-related diseases by administering natural phenolic compounds
10/17/2000US6133295 Pharmaceutical composition
10/17/2000US6133293 Insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action; potent depressive effect on diabetic hyperglycemia; 2,4-thiazolidinediones and oxazolidinediones
10/17/2000US6133288 2,8-di(hydroxy)-5-((2-piperidin-1-yl)ethyoxy-1,4-phenylene)-)-5h -benzo-(e)naphtho(1,2-c)pyran; post-menopausal syndrome, osteoporosis, cardiovascular disorders; uterine fibrosis, endometriosis, and aortal smooth muscle cell proliferation
10/17/2000US6133268 1,4-disubstituted piperazines
10/17/2000US6133265 Treating physiological disorders associated with an excess of neuropeptide y, such as eating disorders, e.g., obesity, bulimia, and certain cardiovascular diseases, e.g., hypertension
10/17/2000US6133254 Treatment of autoimmune diseases
10/17/2000US6133250 Oral 1α-hydroxyprevitamin D in methods for increasing blood level of activated vitamin D
10/17/2000US6133235 Glucagon-like insulinotropic peptides compositions and methods
10/17/2000US6133005 Enzymatic protein; for the treatment of nervous system disorders associated with thamine vitamin deficiency
10/17/2000US6132706 Physiologically acceptable polymer comprising a backbone to which are attached guanidino groups, the polymer having a minimum molecular weight of 10,000.
10/17/2000US6131567 Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
10/17/2000CA2305893A1 Use of maduraphthalazine derivatives as inhibitors of proinflammatory cytokines
10/17/2000CA2178752C N-terminally chemically modified protein compositions and methods
1 ... 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 ... 1298